CTNM

Contineum Therapeutics, Inc.

Contracts

Total Value

Stock Metrics

0.0%

Short % Float

13.5d to cover · Moderate squeeze

98.8%

Inst % Float

10 holders · 2026-06-30

Suvretta Capital M

Top Holder

8.6% of float

32/100

Dilution Score

Medium

67 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

32/100

MEDIUM

Inst: 98.82% · Top: Suvretta Capital Management, LLC

Biotech Analytics

Biotech / Pharma

12.59

Squeeze risk: MODERATEBiotech Grade: F

Insider Buying0

Publications100

Dilution Risk32

Clinical Trials12

Short Interest10